GSK-葛兰素史克股票行情，NYSE: GSK股票价格，图表，新闻

行情

GSK

葛兰素史克

NYSE

实时行情|Nasdaq Last Sale

39.85

+0.77

+1.96%

交易中 15:08 06/23 EDT

开盘

40.53

昨收

39.08

最高

40.58

最低

39.76

成交量

1,095.79万

成交额

52周最高

42.40

52周最低

33.26

市值

1,002.40亿

市盈率(TTM)

13.79

分时

5日

1月

3月

1年

5年

葛兰素史克首席执行官沃姆斯利在战略获得适度支持时争取时间

(Bloomberg) -- Emma Walmsley may have bolstered her position at the top of GlaxoSmithKline Plc, at least for now, following a lukewarm reaction to long-awaited plans to restructure the pharmaceutical giant after years of underperformance.With a potential a...

Bloomberg · 40分钟前

葛兰素史克 (GlaxoSmithKline) 在激进投资者埃利奥特 (Elliott) 出现之际谈论增长前景

marketwatch.com · 3小时前

葛兰素史克刚刚宣布削减股息。为什么它的股票在上涨。

The spinoff of the consumer health business will allow the remaining company to increase sales by more than 5% a year for the next half decade, management said.

Barrons.com · 4小时前

在葛兰素史克和资源名称的推动下，伦敦股市攀升

The FTSE 100 was outperforming European rival indexes on Wednesday, helped by higher oil prices and as shares of GlaxoSmithKline surged after an investor meeting.

MarketWatch · 4小时前

在激进基金 Elliott 的压力下，葛兰素史克公布了雄心勃勃的增长目标。但这足够了吗？

marketwatch.com · 5小时前

随着消费者业务的分裂，葛兰素史克首席执行官誓言“增长的阶梯式变化”

British pharmaceutical giant GlaxoSmithKline faces a crunch meeting with investors after announcing a new strategy for the next decade.

CNBC.com · 6小时前

葛兰素史克承诺增长，但将削减股息

marketwatch.com · 6小时前

葛兰素史克首席执行官谈剥离消费者保健业务

GlaxoSmithKline's stock rose 3.5% in the premarket Wednesday after it detailed plans to spin out its consumer health-care business into a separate company. Glaxo will eventually receive an $11 billion payment from the new company. GlaxoSmithKline CEO Emma ...

CNBC.com · 6小时前

财务预测

实际值（美元）

预测值（美元）

利润表更多

净利润（美元）

同比（%）

资产负债表更多

总资产（美元）

总负债（美元）

资产负债率（%）

现金流表更多

经营现金流（美元）

同比（%）

了解GSK最新的财务预测，通过GSK每股收益，每股净资产，每股现金流等数据分析葛兰素史克近期的经营情况，然后做出明智的投资选择。

分析师评级

4位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测

分析师预测GSK价格均价为49.17，最高价位54.50，最低价为42.00。

EPS

机构持股

总机构数: 1,103

机构持股: 3.45亿

持股比例: 13.71%

总股本: 25.16亿

类型机构数股数

增持

291

4,977.43万

建仓

1,307.76万

减持

286

3,422.12万

平仓

356.20万

业绩
资产分布
分红历史

暂无数据

所属板块

制药

-0.45%

制药与医学研究

-0.38%

高管信息

Non-Executive Chairman/Independent Director

Jonathan Symonds

Chief Executive Officer/Executive Director

Emma Walmsley

Chief Financial Officer/Executive Director

Iain Mackay

Corporate Executive

Roger Connor

Corporate Executive

Brian McNamara

Corporate Executive

Luke Miels

Corporate Executive

Abbas Hussain

Corporate Executive

Regis Simard

Corporate Executive

Phil Thomson

Corporate Executive

Deborah Waterhouse

Senior Vice President/General Counsel

James Ford

Senior Vice President/Director of Human Resources

Diana Conrad

Senior Vice President

Nick Hirons

Senior Vice President

Sally Jackson

Chief Technology Officer

Karenann Terrell

Chief Scientific Officer/Executive Director

Hal Barron

Other

David Redfern